Literature DB >> 23534367

Hemicrania continua responsive to botulinum toxin type a: a case report.

Modar Khalil1, Fayyaz Ahmed.   

Abstract

BACKGROUND: Hemicrania continua (HC) is a primary headache disorder with full response to indomethacin as one of its diagnostic criteria; however, indomethacin's side effects could limit its use in HC. CASE RESULT: We report a 33-year-old lady whose headache fulfilled the criteria for HC, but the patient developed gastric side effect to indomethacin and did not respond to other pharmacological treatments; however, injecting botulinum toxin type A has led to complete resolution of all of her symptoms. DISCUSSION: We hypothesize the mechanism by which botulinum toxin type A has led to our results through reviewing recent functional neuroimaging findings used to understand the pathophysiology of different primary headache disorders.
© 2013 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23534367     DOI: 10.1111/head.12086

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  10 in total

Review 1.  Hemicrania continua.

Authors:  Robert W Charlson; Matthew S Robbins
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 2.  When indomethacin fails: additional treatment options for "indomethacin responsive headaches".

Authors:  Shuhan Zhu; Brian McGeeney
Journal:  Curr Pain Headache Rep       Date:  2015-03

Review 3.  Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.

Authors:  Carlo Lovati; Luca Giani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 4.  Hemicrania Continua: a Clinical Perspective on Diagnosis and Management.

Authors:  Amit Mehta; Priyanka Chilakamarri; Adeel Zubair; Deena E Kuruvilla
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-17       Impact factor: 5.081

Review 5.  Diagnose and adios: practical tips for the ongoing evaluation and care of TAC patients taking indomethacin.

Authors:  Laura B Xanders; Jessica Ailani
Journal:  Curr Pain Headache Rep       Date:  2015

Review 6.  Trigeminal autonomic cephalalgias: beyond the conventional treatments.

Authors:  Sarah Miller; Manjit Matharu
Journal:  Curr Pain Headache Rep       Date:  2014

7.  OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients.

Authors:  Sarah Miller; Fernando Correia; Susie Lagrata; Manjit S Matharu
Journal:  J Headache Pain       Date:  2015-03-05       Impact factor: 7.277

Review 8.  Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.

Authors:  Carlo Baraldi; Lanfranco Pellesi; Simona Guerzoni; Maria Michela Cainazzo; Luigi Alberto Pini
Journal:  J Headache Pain       Date:  2017-07-20       Impact factor: 7.277

Review 9.  Hemicrania continua: clinical review, diagnosis and management.

Authors:  Sanjay Prakash; Payal Patel
Journal:  J Pain Res       Date:  2017-06-29       Impact factor: 3.133

Review 10.  Hemicrania Continua.

Authors:  Sanjay Prakash; Bansi Adroja
Journal:  Ann Indian Acad Neurol       Date:  2018-04       Impact factor: 1.383

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.